IGMS
vs
S&P 500
IGMS
S&P 500
Over the past 12 months, IGMS has underperformed S&P 500, delivering a return of -20% compared to the S&P 500's +14% growth.
Stocks Performance
IGMS vs S&P 500
Performance Gap
IGMS vs S&P 500
Performance By Year
IGMS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
IGM Biosciences Inc
Glance View
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 192 full-time employees. The company went IPO on 2019-09-18. The company has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
